HD-OPM Archive

Statin myths: dementia, cancer, testosterone, mitochondria and the elderly

What randomized trials, large cohorts and genetic studies say about the claims that statins cause dementia, cancer, low testosterone, mitochondrial damage or muscle and liver harm, and what the evidence says about starting or stopping statins in older adults.

15 min read52 group posts cited47 studies discussed4 chartsEvidence through Nov 2026AI Summary of posts by Louis Nervegna and Gokhan Can
Key takeaways
  • In STAREE (9,971 adults aged 70 and over, atorvastatin 40 mg versus placebo, median 5.9 years) major cardiovascular events fell 30% (6.0% versus 8.3%), with no significant rise in dementia (hazard ratio 1.03) and serious adverse events of 2.7% in both groups.
  • Pooled randomized trials found no effect of statins on cancer: an odds ratio of 0.99 for both cancer incidence and cancer mortality across 35 trials.
  • Observational studies mostly find lower dementia risk in statin users (for example 20% lower dementia and 32% lower Alzheimer's risk in one pooled analysis), but this is association only, and the two trials in existing Alzheimer's disease were neutral.
  • Statins lower total testosterone by only about 9-13 ng/dL on average, against a normal range of roughly 300-1,000 ng/dL, and often improve erectile function scores in men with high cholesterol.
  • In the STREAM trial of 1,880 adults over 70, stopping statins was followed by more heart attacks, strokes or deaths (12.7% versus 9.2%), and the safety board suggested discussing restarting.
In this summary
  1. Where the myths come from: one pathway, several fears
  2. Dementia and memory
  3. Cancer
  4. Testosterone and sexual function
  5. Mitochondria and CoQ10
  6. Muscle, liver and blood sugar
  7. Statins in older adults
  8. How to weigh online claims
  9. What this means for you
  10. Frequently asked questions
  11. The evidence behind this summary

Social media is full of claims that statins cause dementia, feed cancer, destroy testosterone, poison mitochondria, drain the brain of cholesterol or are useless in the elderly. The group's posts, mostly by admin Louis Nervegna with contributions from Gokhan Can, go through these claims one by one against the published trials, meta-analyses and genetic studies.

The short version is that the best available evidence does not support the claims of serious harm. Randomized trials show no increase in cancer or dementia, and the observational data lean toward a neutral or protective association. Some real, smaller effects exist and are discussed below: a modest rise in blood sugar, muscle symptoms in some people, and a drop in total testosterone too small to matter for most men.123

The posts are also frank about where evidence is thin. Many of the encouraging dementia findings are observational and cannot prove cause and effect, and some mechanistic arguments (for example about mitochondria) are the admins' interpretation rather than trial results. This article tries to keep those categories separate. It is a summary of group discussion, not medical advice.

1.03hazard ratio for dementia on atorvastatin versus placebo in STAREE: no significant increase4
0.99odds ratio for cancer incidence across 35 randomized statin trials2
9–13 ng/dLaverage drop in total testosterone, against a normal range of about 300–1,0003
12.7% vs 9.2%heart attack, stroke or death after stopping versus continuing statins past 70 (STREAM)5

Where the myths come from: one pathway, several fears

Statins block an enzyme, HMG-CoA reductase, in the mevalonate pathway that the body uses to make cholesterol. The same pathway also produces CoQ10, so statins lower CoQ10 as well.8 Cholesterol is also the raw material for hormones such as testosterone.3 A chain of logical-sounding fears follows: less cholesterol must mean less testosterone, a starved brain and damaged cells. The sections below check each link against the evidence.

Dementia and memory

Does cholesterol lowering starve the brain?

Louis explains that the brain makes all of its own cholesterol locally, separate from the cholesterol in the blood, and the blood-brain barrier does not let blood cholesterol in. Drugs such as PCSK9 inhibitors and ezetimibe act only on blood cholesterol and so have no effect on brain cholesterol production.9 Lipophilic (fat-soluble) statins like atorvastatin do cross the barrier; hydrophilic statins like rosuvastatin do so poorly.69

What observational studies show

Several pooled analyses of observational data point toward lower dementia risk among statin users:

  • A meta-analysis of observational studies found statin use associated with 20% lower dementia risk (36 studies, odds ratio 0.80) and 32% lower Alzheimer's risk (21 studies, odds ratio 0.68). Its authors noted that this confirms the absence of a neurocognitive risk and called for randomized trials.10
  • A 2025 meta-analysis of 55 observational studies in about 7 million people found 14% lower all-cause dementia and 18% lower Alzheimer's risk. Louis corrected a video that described it as a clinical-trial analysis: these were cohort and case-control studies, not randomized trials.11 Another summary of the same analysis reports a 63% lower risk after at least three years of use, stronger effects in type 2 diabetes, and a 28% reduction with rosuvastatin.1213 Those figures differ markedly from the 14% pooled number, which is a reminder to treat subgroup results cautiously.
  • A report on a heart-failure cohort found 20% lower dementia risk,14 a Swedish registry of about 15,600 people with Alzheimer's or mixed dementia found slightly slower cognitive decline in statin users (about 0.63 points on the MMSE test over three years),15 a Danish study of people with type 2 diabetes tied earlier statin starts to about 15% lower dementia over a decade,16 and a very large analysis described as covering about 125 million people reported lower Alzheimer's risk and lower mortality.17

The limits matter. The Swedish researchers themselves said their study "doesn't prove causality" and did not mean that people with dementia should be treated with statins, though they saw no support for withholding a statin from someone who needs it.15 Louis also notes that single observational studies can be cherry-picked in either direction but that, taken as a whole, they suggest a protective effect or at least no harm.18 One of the large analyses he shared acknowledges that randomized trials show a neutral effect.17

Observational studies link statins to less dementiaLower risk among statin users in two meta-analyses of observational (cohort and case-control) studies
Dementia (36 studies)20% lower
Alzheimer's disease (21 studies)32% lower
All-cause dementia (2025, 55 studies, about 7 million people)14% lower
Alzheimer's disease (2025, 55 studies)18% lower
Associations only; they cannot prove that statins protect the brain. Randomized trials so far are neutral. Source: 1011
Show data
Value
Dementia (36 studies)20% lower
Alzheimer's disease (21 studies)32% lower
All-cause dementia (2025, 55 studies, about 7 million people)14% lower
Alzheimer's disease (2025, 55 studies)18% lower
Curves from the very large analysis Louis shared: over follow-up, people exposed to statins stayed free of Alzheimer's disease and alive more often than those not exposed, with little difference for early-onset Alzheimer's or other degenerative neurological conditions. Observational data.
Curves from the very large analysis Louis shared: over follow-up, people exposed to statins stayed free of Alzheimer's disease and alive more often than those not exposed, with little difference for early-onset Alzheimer's or other degenerative neurological conditions. Observational data.17

What randomized trials show

  • Two trials gave statins to people who already had mild to moderate Alzheimer's disease: simvastatin (406 participants, 18 months) and atorvastatin 80 mg (the LEADe trial, 640 participants, 72 weeks). Neither slowed nor worsened progression, and simvastatin showed no increase in adverse events.19
  • The SAMSON trial of people who had stopped statins because of side effects also found that complaints of short-term memory loss were a nocebo effect, according to Louis.6
  • STAREE, a large trial in healthy older adults, found no significant increase in dementia (hazard ratio 1.03).4 Before it reported, Louis reasoned that because it was not stopped early for harm, there was no major harm signal; the PREVENTABLE trial's principal investigator made a similar point about its safety board.112
  • Two large trials were designed specifically to test dementia prevention: PREVENTABLE (about 20,000 adults aged 75 and over, atorvastatin 40 mg, started in 2020) and STAREE.2021 STAREE's co-primary outcome of disability-free survival (which includes staying free of dementia) was not significantly improved, 12.8% versus 13.6% (hazard ratio 0.94).7

Louis's reading is that waiting until old age to start is unlikely to either help or harm the brain, and that earlier starts may be needed to see any protective effect.16

Genetic evidence

A 2025 Mendelian randomization study (which uses gene variants that act like lifelong drug exposure) in about one million people found that variants mimicking statins and ezetimibe were linked to a 76% and 82% lower dementia risk per roughly 40 mg/dL drop in non-HDL cholesterol, while PCSK9-like variants showed no benefit.2223 Louis and Gokhan argue this helps explain why short late-life trials may show nothing: lifelong exposure may matter, and genetic studies are not vulnerable to the reverse causality that can distort observational data, because cholesterol often falls in the years before a dementia diagnosis.2223 This is an argument from genetics rather than a trial of a statin.

Genes that mimic statins and ezetimibe go with less dementiaLower dementia risk per roughly 40 mg/dL lower non-HDL cholesterol from gene variants that mimic each drug target, Mendelian randomization in about one million people
Statin-like (HMGCR)76% lower
Ezetimibe-like (NPC1L1)82% lower
CETP-like (obicetrapib pathway)70% lower
Lifelong genetic exposure, not a drug trial. PCSK9-like variants showed no benefit. Source: 22
Show data
Value
Statin-like (HMGCR)76% lower
Ezetimibe-like (NPC1L1)82% lower
CETP-like (obicetrapib pathway)70% lower

APOE4 carriers and the desmosterol test

A neurologist's article that Louis recommends separates two questions: treating people who already have mild cognitive impairment or Alzheimer's, where the case is weak, and vascular prevention in people with high LDL, including those who carry the APOE4 gene, which he suggests deserves a careful discussion with a clinician.24 Louis also doubts the Boston Heart desmosterol test sold to healthy people as an Alzheimer's risk check, arguing that lower desmosterol in healthy people has been linked to lower, not higher, dementia risk.25

Cancer

Louis and Gokhan summarize several analyses of randomized trials:

  • A 2012 analysis of 22 randomized trials (134,537 participants, median follow-up 4.8 years) found annual cancer incidence of 1.4% and cancer mortality of 0.5% in both statin and control groups. A 2023 meta-analysis of 35 trials found an odds ratio of 0.99 for incidence and 0.99 for mortality, with no effect by cancer type, statin type or duration.226
  • A 2017 analysis of 21 placebo-controlled trials (65,196 participants) found a relative risk of 0.97,2 and the 27-trial CTT analysis of women and men saw no adverse effect on cancer incidence.27
  • After a long follow-up, WOSCOPS (5 years of pravastatin) showed lower all-cause and cardiovascular mortality at 20 years with no increase in cancer or non-cardiovascular mortality.28
Identical cancer rates on statin and controlAnnual rates in a 2012 analysis of 22 randomized trials (134,537 participants, median 4.8 years)
StatinControl
Cancer incidence per year1.4%1.4%
Cancer death per year0.5%0.5%
Source: 26
Show data
StatinControl
Cancer incidence per year1.4%1.4%
Cancer death per year0.5%0.5%

So the claim that statins cause cancer has not held up in randomized data, and the posts also caution against the opposite exaggeration. Statins mostly failed to improve outcomes when tested as cancer treatments, but they did not worsen them or make existing cancer spread.29 Gokhan's summary is that statins "neither cause nor cure cancer" in general populations.26

Some narrower findings are more hopeful but weaker. Observational data link statins to lower advanced and fatal prostate cancer and, after a high-risk prostate cancer diagnosis, to 42% lower prostate cancer death,230 and to roughly 35% lower odds of liver cancer.31 Laboratory studies suggest statins may block an inflammatory pathway involved in some cancers and that statins combined with sildenafil may limit metastasis in preclinical models.3233 These are preclinical or observational leads, not proof of benefit.

Testosterone and sexual function

Because cholesterol is the raw material for testosterone, the fear is intuitive. Gokhan's post reviewing the research reports that meta-analyses find a statistically significant but small reduction in total testosterone, about 9-13 ng/dL, against a normal range of about 300-1,000 ng/dL, which he describes as rarely enough to push a healthy man into low testosterone.3 He adds that statins often improve erectile function scores in men with high cholesterol and erectile dysfunction, by about one-third to one-half of the effect of Viagra as stated in the post, through better endothelial (blood vessel lining) function. He notes that erectile dysfunction is often an early sign of heart disease.3

Mitochondria and CoQ10

"Statins damage mitochondria"

Louis argues that the mild mitochondrial stress statins cause is hormetic: a small stress that switches on protective pathways, similar to how metformin, exercise and calorie restriction are thought to work, rather than harm. He cites a 2006 study showing statins activate the AMPK energy-sensing pathway and a 2012 paper on "mitohormesis" as a possible pleiotropic effect.34353637 He stresses that dose determines whether such stress is beneficial or toxic, and that outright mitochondrial damage requires doses far above those used in people.3536 These are mechanistic arguments from the admin and from laboratory work; they are not a clinical trial showing mitochondrial benefit in patients.

"Statins deplete CoQ10, so I need a supplement"

The CoQ10 point is partly true. Statins do lower plasma and immune-cell CoQ10, because both depend on the mevalonate pathway.838 The effect on CoQ10 in muscle tissue, however, is barely detectable, and a post Louis shared concludes that CoQ10 supplements will not reliably prevent statin muscle symptoms, since the best-designed trials show no benefit.38 Louis agrees that most CoQ10 trials for statin muscle pain have failed, though he considers it reasonable to try CoQ10 since statins do lower its production.39 He is himself a fan of CoQ10 for other reasons.38

Muscle, liver and blood sugar

Muscle

Louis says rhabdomyolysis (serious muscle breakdown) from statins occurs in about 1 in 100,000 people, or perhaps 1 in 10,000 if being conservative, and is very different from the more common muscle aches.40 He argues that statin myopathy occurs in people with a genetic susceptibility linked to variants in HMG-CoA reductase-related genes,3940 and that as much as 90% of reported statin side effects may be nocebo effect, based on the SAMSON trial.639 He cites nutrition researcher Tim Spector, who had a mini stroke at 53, as an example of someone who decided his muscle cramps were nocebo-driven and resumed a statin.41 Louis also recommends lowering the dose, switching statins (for example to pitavastatin or pravastatin) or using non-statin LDL-lowering drugs when muscle pain is troublesome.39

Liver

A review shared by Louis says statins were once considered harmful to the liver, but current evidence suggests possible benefit in chronic liver disease, though trials are still needed.42 Statin use is associated in observational data with lower liver cancer and decompensation.3143

A figure from the liver study Louis shared: among patients with high or intermediate fibrosis-4 (FIB-4) liver scores at baseline, statin users more often moved into the lower score groups after three years, in both the whole population and a propensity-matched comparison. Observational data.
A figure from the liver study Louis shared: among patients with high or intermediate fibrosis-4 (FIB-4) liver scores at baseline, statin users more often moved into the lower score groups after three years, in both the whole population and a propensity-matched comparison. Observational data.43

Blood sugar

The diabetes signal is real but small. In a pooled analysis of 13 trials (91,140 patients), treating 255 people for four years caused one extra case of diabetes while preventing 5.4 cardiovascular events.6 Louis also points out that a keto diet produces a much larger temporary muscle insulin resistance than statins do, and that both effects reverse when the diet or drug is stopped.44

Statins in older adults

The STAREE trial

STAREE enrolled 9,971 adults aged 70 and over with no cardiovascular disease, diabetes or dementia (mean age 74.7, 52% women), giving atorvastatin 40 mg or placebo for a median of 5.9 years.47 Major cardiovascular events fell from 8.3% to 6.0% (hazard ratio 0.70).7 Heart attacks and revascularizations were each about 43% lower, with no significant increase in dementia or all-cause mortality and serious adverse events of 2.7% in both groups.4 One reading puts the number needed to treat at 37 over about six years, with benefit holding in people aged 75 and over and a starting LDL near 127 mg/dL.45 On the other hand, disability-free survival, one of the two primary outcomes, was not significantly improved, and overall mortality did not differ significantly.745 Louis's pre-results prediction that STAREE would show neither major harm nor spectacular benefit on the brain endpoints was therefore broadly borne out, though the cardiovascular benefit was substantial.14

STAREE: fewer cardiovascular events, no extra harm9,971 adults aged 70 and over without cardiovascular disease, atorvastatin 40 mg versus placebo, median 5.9 years
Atorvastatin 40 mgPlacebo
Major cardiovascular events6.0%8.3%
Disability-free survival endpoint12.8%13.6%
Serious adverse events2.7%2.7%
Major cardiovascular events hazard ratio 0.70 (0.61–0.82); disability-free survival hazard ratio 0.94, not significant; dementia hazard ratio 1.03, not significant. Source: 47
Show data
Atorvastatin 40 mgPlacebo
Major cardiovascular events6.0%8.3%
Disability-free survival endpoint12.8%13.6%
Serious adverse events2.7%2.7%

Starting late, and stopping

  • A JAMA study of 326,981 mostly male veterans aged 75 and over without cardiovascular disease found that those who started statins had 25% lower overall mortality and 20% lower death from heart attack or stroke. It is observational and shows association only.46
  • Observational studies of older veterans linked new statin use to less frailty, and the group notes that both STAREE and PREVENTABLE track it. Randomized confirmation is still needed.4748
  • In the STREAM trial, 1,880 adults aged 70 and over without known cardiovascular disease were randomized to continue or stop statins. Heart attack, ischemic stroke or death occurred in 12.7% of those who stopped and 9.2% of those who continued, about 38% more events in relative terms. The trial was declared noninferior under its predefined margin, and stopping brought no meaningful improvement in muscle pain, quality of life, falls or sarcopenia; the safety board recommended that those who stopped discuss restarting. Louis argues that "noninferior" does not mean identical, and that stopping simply because someone turned 70 is not something he would recommend, while acknowledging that frailty, life expectancy, adverse effects and individual risk matter.5
  • A discussion of evidence after age 75, including STAREE and the SAGA/SITE trials, was recommended by Louis.49

How to weigh online claims

Louis's general advice to people at high risk is to find a good cardiologist, to add natural or alternative approaches to treatment rather than replace it, and to reduce medications only together with that cardiologist if the condition markedly improves. He warns against drawing conclusions from one cherry-picked study out of many.50 He also argues that statin trials look modest in absolute terms only because they run for about five years: absolute risk reductions of 1.1% to 4.7% in such trials are, in his words, large against a roughly 20% lifetime risk.5152

What this means for you

  • If you are worried about dementia, the group's posts point to a neutral or possibly favorable picture. Statins did not increase dementia in STAREE and the trials in existing Alzheimer's were neutral. Louis notes that rosuvastatin barely crosses into the brain, while lipophilic atorvastatin does and was chosen for the dementia-prevention trials.491920
  • If you worry about cancer, randomized data show no effect either way.226
  • If you notice muscle aches, the admins suggest discussing a lower dose, a different statin or a non-statin drug with your doctor, rather than assuming the cause, since blinded trials point to a large nocebo component.639
  • If you are over 70, Louis does not recommend stopping a statin simply because of age, but he agrees that frailty, life expectancy, side effects and individual risk matter, so the decision is one to discuss with your doctor. STAREE and STREAM both showed cardiovascular differences.57
  • Check claims against randomized trials and meta-analyses and not against a single observational result or an influencer's summary.1850

Frequently asked questions

Do statins cause dementia?

Randomized evidence does not show that they do. STAREE found no significant rise in dementia, and observational meta-analyses mostly find lower risk, although those cannot prove protection.410

Do statins cause cancer?

Across 22 to 35 randomized trials, no. The odds ratio for cancer incidence was 0.99 in a 2023 meta-analysis.226

Do statins destroy testosterone?

They lower total testosterone slightly, about 9-13 ng/dL on average, which is small against a normal range of 300-1,000 ng/dL, and often improve erectile function scores in men with high cholesterol.3

Do statins damage mitochondria or deplete CoQ10?

Statins do lower plasma CoQ10, but muscle CoQ10 barely changes and CoQ10 supplements have not reliably prevented muscle symptoms. Louis argues that the mild mitochondrial stress is hormetic rather than harmful; this is a mechanistic argument.3538

Are statins pointless in older people?

STAREE showed a 30% reduction in major cardiovascular events in healthy adults aged 70 and over, though without a significant gain in disability-free survival. In STREAM, stopping statins at 70 or over was followed by more events.57

The evidence behind this summary47 studies · 13 meta-analyses · 9 trials · 3 MR · 10 observational

The 52 group posts cited above discuss 47 studies and sources. Their mix of study designs shows how much rests on randomized trials and meta-analyses, which can show cause and effect, and how much on observational, lab or animal work, which mostly cannot.

Meta-analyses 13Randomized trials 9Mendelian randomization 3Observational studies 10Reviews & guidelines 7Animal & lab studies 3Other sources 2

Strongest evidence discussed

All 47 studies and sources
Sources from the group (52)
  1. STAREE statin trial in 10,000 people over 70 is complete; no major harm or big benefit Louis Nervegna · May 26, 2026 · Facebook
  2. Statin RCT meta-analyses show no increase or decrease in cancer risk Louis Nervegna · Dec 31, 2024 · Facebook
  3. Statins lower testosterone only slightly and often improve erectile function Gokhan Can · Jan 03, 2026 · Facebook
  4. STAREE: atorvastatin cut major CV events 30% in adults 70+ with no rise in dementia Louis Nervegna · Nov 01, 2026 · Facebook
  5. STREAM: why 'noninferior' does not make stopping statins at age 70 safe Louis Nervegna · Nov 15, 2026 · Facebook
  6. What cardiologists say about statins: dementia, muscle pain, diabetes, primary prevention Louis Nervegna · Jan 13, 2026 · Facebook
  7. STAREE: atorvastatin cut major CV events 30% in adults 70+, not disability-free survival Louis Nervegna · Aug 29, 2026 · Facebook
  8. CoQ10 shuttles electrons in the mitochondrial chain, relevant to statin users Louis Nervegna · May 07, 2026 · Facebook
  9. Only lipophilic statins like atorvastatin enter the brain; PCSK9 drugs and ezetimibe don't Louis Nervegna · Oct 18, 2025 · Facebook
  10. Statin use linked to 20% lower dementia and 32% lower Alzheimer's risk in meta-analysis Louis Nervegna · Oct 22, 2024 · Facebook
  11. Statin users had 14% lower dementia risk in a meta-analysis of 7 million people Louis Nervegna · Aug 05, 2026 · Facebook
  12. Statins for 3+ years linked to 63% lower dementia risk in a 55-study meta-analysis Louis Nervegna · Feb 12, 2025 · Facebook
  13. Statins do not cause dementia or cognitive decline and may be protective in cohorts Louis Nervegna · Mar 13, 2026 · Facebook
  14. Statin use linked to 20% lower dementia risk in heart-failure patients (Hong Kong study) Louis Nervegna · Jan 25, 2024 · Facebook
  15. Statin use linked to slower cognitive decline in Alzheimer's and mixed dementia Louis Nervegna · Dec 25, 2025 · Facebook
  16. Statins started within a year of type 2 diabetes tied to 15% lower dementia risk Louis Nervegna · Sep 04, 2026 · Facebook
  17. Analysis of 125 million statin users links statins to lower Alzheimer's risk and mortality Louis Nervegna · Apr 01, 2026 · Facebook
  18. Observational, randomized and genetic evidence all argue against statins causing dementia Louis Nervegna · Nov 01, 2026 · Facebook
  19. Two RCTs found statins neither helped nor harmed Alzheimer's disease progression Louis Nervegna · Jun 23, 2025 · Facebook
  20. PREVENTABLE: 20,000-person trial of atorvastatin 40 mg to prevent dementia over age 75 Louis Nervegna · Jun 23, 2025 · Facebook
  21. STAREE statin trial in adults over 70 is finished; results due in second half of 2026 Louis Nervegna · May 18, 2026 · Facebook
  22. Statin- and ezetimibe-like gene variants linked to 76-82% lower dementia risk per 40 mg/dL Louis Nervegna · Aug 28, 2026 · Facebook
  23. Mendelian randomization in 1 million people: statin-like genetics cut dementia risk 76-82% Gokhan Can · Nov 06, 2025 · Facebook
  24. Statins in APOE4 carriers: the best case is vascular prevention, not Alzheimer's treatment Louis Nervegna · Feb 28, 2026 · Facebook
  25. Boston Heart's desmosterol test is likely a waste of money, argues Louis Louis Nervegna · Jan 15, 2024 · Facebook
  26. Statins neither cause nor cure cancer: meta-analyses of randomized trials show no effect Gokhan Can · Dec 31, 2024 · Facebook
  27. Statins work as well in women as men: 27-trial CTT meta-analysis of 174,000 participants Louis Nervegna · Dec 19, 2023 · Facebook
  28. WOSCOPS 20-year follow-up: 5 years of pravastatin gave lasting mortality and event benefit Gokhan Can · Apr 07, 2026 · Facebook
  29. Statins did not improve cancer outcomes in trials but did not worsen them either Louis Nervegna · Aug 06, 2026 · Facebook
  30. Statins after high-risk prostate cancer diagnosis linked to 42% lower cancer death Louis Nervegna · Dec 05, 2024 · Facebook
  31. Ezetimibe-type absorption inhibitors linked to 31% lower liver cancer odds; statins 35% Louis Nervegna · Aug 01, 2024 · Facebook
  32. Statins block an IL-33 inflammation pathway that may drive inflammation-linked cancers Louis Nervegna · Dec 05, 2024 · Facebook
  33. Statin plus sildenafil may block cancer metastasis in preclinical models Louis Nervegna · Jul 27, 2026 · Facebook
  34. Statins activate AMPK via mild mitochondrial stress, which Louis argues is beneficial Louis Nervegna · Nov 23, 2023 · Facebook
  35. Mild mitochondrial stress from statins is hormetic, not harmful Louis Nervegna · Nov 17, 2025 · Facebook
  36. Statins activate AMPK, the same longevity pathway as metformin Louis Nervegna · Nov 11, 2025 · Facebook
  37. Statins create mild mitochondrial stress that triggers protective mitohormesis Louis Nervegna · Nov 11, 2025 · Facebook
  38. CoQ10 supplements do not reliably prevent statin muscle symptoms Louis Nervegna · Apr 16, 2026 · Facebook
  39. What to try for statin muscle pain: lower dose, other statins, non-statins; beware nocebo Louis Nervegna · Feb 17, 2025 · Facebook
  40. Statin muscle toxicity overstated: rhabdomyolysis ~1 in 100,000; sarcopenia use studied Louis Nervegna · Dec 16, 2024 · Facebook
  41. Tim Spector had a mini stroke at 53 and now takes statins Louis Nervegna · Jul 09, 2026 · Facebook
  42. Statins may benefit chronic liver disease rather than harm it, per a review Louis Nervegna · Jul 16, 2024 · Facebook
  43. Statin use linked to lower liver cancer and decompensation in chronic liver disease Louis Nervegna · May 19, 2025 · Facebook
  44. Keto causes bigger temporary insulin resistance than statins, so statin fear is overplayed Louis Nervegna · Sep 16, 2024 · Facebook
  45. STAREE: statins reduced events 30% in healthy adults 70+, NNT 37, no dementia increase Louis Nervegna · Aug 29, 2026 · Facebook
  46. Starting statins at 75 or older linked to 25% lower death rate in 326,981 veterans Louis Nervegna · May 12, 2025 · Facebook
  47. New statin use linked to less frailty in older veterans; STAREE will test it Louis Nervegna · Jun 10, 2026 · Facebook
  48. Older veterans starting statins were less likely to develop frailty Louis Nervegna · Jun 10, 2026 · Facebook
  49. Statins after age 75: evidence review including the STAREE and SAGA/SITE trials Louis Nervegna · Sep 17, 2026 · Facebook
  50. At high risk of a heart attack? Find a good cardiologist and add, don't replace, treatment Louis Nervegna · Feb 26, 2024 · Facebook
  51. A 1.1-4.7% absolute risk reduction from statins is large against a 20% lifetime risk Louis Nervegna · Apr 28, 2024 · Facebook
  52. Statin absolute risk reduction is small over years but can exceed 10% over a lifetime Louis Nervegna · Nov 10, 2025 · Facebook

Keep exploring

Related research summaries

Topics and hashtags in this summary